Diclofenac Sodium

CHEMBL1034 Phase 4 Zugelassen Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
318.1 g/mol
LogP
Phase
4

The sodium salt and most common oral formulation of diclofenac, an NSAID used for chronic inflammatory conditions including rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis. Extended-release tablets allow twice-daily dosing.

Molekularmasse

318,1000 g/mol

TPSA

52,20 Ų

Therapeutische Bereiche

Wirkmechanismus

Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanismus

Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.

2D-Struktur

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

O=C([O-])Cc1ccccc1Nc1c(Cl)cccc1Cl.[Na+]

InChI

InChI=1S/C14H11Cl2NO2.Na/c15-10-5-3-6-11(16)14(10)17-12-7-2-1-4-9(12)8-13(18)19;/h1-7,17H,8H2,(H,18,19);/q;+1/p-1

Molecular Formula

C14H10Cl2NNaO2

HBD / HBA

1 / 3

Rotierbare Bindungen

4

Schwere Atome

20

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

The sodium salt and most common oral formulation of diclofenac, an NSAID used for chronic inflammatory conditions including rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis. Extended-release tablets allow twice-daily dosing.

Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.

Yes, Diclofenac Sodium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1034. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 5018304. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.